new molecules and indications for glp 1 medicines GLP-1 GLP-1 Market Trends and Global

Results: From randomization to year 1, liraglutide 3.0 mg recipients lost 5.8 kg (95% confidence interval 3.78.0) more weight than those on placebo and 3.8 kg (1.66.0) more than those on orlistat ( P 0.0001

In general the report is well structured

[DOI] [PMC free article] [PubMed] [Google Scholar] 23.Capristo E, Panunzi S, De Gaetano A, Spuntarelli V, Bellantone R, Giustacchini P, Birkenfeld AL, Amiel S, Bornstein SR, Raffaelli M, Mingrone G

Every Wellstar team member is provided the opportunity to anonymously take the survey, and in 2023, 87% of Wellstar team members completed it

Mounjaro is usually covered for type 2 diabetes, while Zepbound may be approved for chronic weight management with prior authorization